Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
house dust mite allergen + rhinovirus 16
- Development stage
- Preclinical
- Lead developer
- Maastricht University Medical Center+
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual, Subcutaneous
01
Overview
House dust mite allergen + rhinovirus 16 is an experimental combination of biological agents used in a clinical research setting to model and investigate the interaction between allergen-induced airway inflammation and viral-induced asthma exacerbations. The combination consists of an inhaled house dust mite allergen extract and nasally administered live Rhinovirus 16 (RV16). The house dust mite allergen provokes a Type 2 inflammatory response characterized by increased sputum eosinophils and exhaled nitric oxide. [14] RV16, a common cold virus, induces a distinct inflammatory profile characterized by an increase in sputum neutrophils and neutrophil elastase. A clinical study in patients with mild to moderate asthma found that sequential exposure to a low dose of the allergen followed by RV16 infection did not result in a synergistic or additive effect on clinical or inflammatory outcomes, suggesting that this level of preceding allergen exposure is not a key determinant for the severity of RV-induced exacerbations.
- Other names
- house dust mite allergen + RV16
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on house dust mite allergen + rhinovirus 16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on house dust mite allergen + rhinovirus 16.